“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

The full results of a phase 3 clinical trial showed that patients with moderate-to-severe active systemic lupus erythematosus (SLE) who received standard treatment achieved greater reductions in ...

The prescribed dosage for Hizentra may depend on a person’s individual treatment plan. Factors like your medical history and body weight may affect your dosage. Hizentra is a prescription drug used to ...

The FDA is accelerating approval for sibeprenlimab, a monoclonal antibody that inhibits APRIL in IgAN pathogenesis. The US Food and Drug Administration (FDA) has granted accelerated approval status to ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...

Efgartigimod demonstrated superior efficacy over IVIG in improving MG-ADL and QMG scores in myasthenia gravis patients. Patients treated with efgartigimod experienced faster symptom improvement and ...

The prescribed dosage for Hizentra (immune globulin subcutaneous [human]) may vary depending on an individual’s treatment plan. Other factors, including your specific diagnosis, body weight, and ...

Plasma-derived immunoglobulin replacement therapy (IRT) is one of the mainstays of supportive management for many inborn errors of immunity, primarily those affecting the adaptive immune system which ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.